Hostname: page-component-78c5997874-dh8gc Total loading time: 0 Render date: 2024-11-17T14:09:07.589Z Has data issue: false hasContentIssue false
  • English
  • Français

Radiotherapy with Concurrent and Adjuvant Temozolomide: A New Standard of Care for Glioblastoma Multiforme

Published online by Cambridge University Press:  15 February 2006

Warren P. Mason ,
René O. Mirimanoff  and
Roger Stupp
Warren P. Mason
Affiliation:
Department of Medicine, Princess Margaret Hospital and the University of Toronto, Toronto, Canada; Email: [email protected]
René O. Mirimanoff
Affiliation:
Department of Radiation Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Email: [email protected]
Roger Stupp
Affiliation:
Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland; Email: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Keywords

temozolomideglioblastomaclinical trialneurotherapeuticsradiotherapyquality of life
Type
Review Article
Information
Progress in Neurotherapeutics and Neuropsychopharmacology , Volume 1 , Issue 1 , January 2006 , pp. 37 - 52
Copyright
© 2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Brada, M., Hoang-Xuang, K., Rampling, R., et al. (2001). Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse. Annals of Oncology, 12, 259–266.Google Scholar
Brandes, A., Vastola, F., Basso, U., et al. (2003). A prospective study on glioblastoma in the elderly. Cancer, 97, 657–662.Google Scholar
Brock, C., Newlands, E., Wedge, S., et al. (1998). Phase I trial of temozolomide using an extended continuous oral schedule. Cancer Research, 58, 4363–4367.Google Scholar
Burger, P., & Scheithauer, B. (1994). Tumors of the Central Nervous System, Washington, D.C: Armed Forces Institute of Pathology.
Cairncross, J.G., Ueki, K., Zlatescu, M.C., et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of National Cancer Institute, 90, 1473–1479.Google Scholar
Cairncross, J.G., Seiferheld, W., Shaw, E., et al. (2004). An intergroup randomized controlled clinical trial (RTC) of chemotherapy plus radiation (RT) versus RT alone for pure and mixed anaplastic oligodendrogliomas: Initial report of RTOG 94-02. Journal of Clinical Oncology, 22 (July 15 Suppl.), 1500.Google Scholar
Chang, C., Horton, J., Schoenfeld, D., et al. (1983). Comparison of postoperative radiotherapy and combined postoperative radiotherapy and chemotherapy in the multidisciplinary management of malignant gliomas. Cancer, 52, 997–1007.Google Scholar
Chinot, O.L., Barrie, M., Frauger, E., et al. (2004). Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer, 100, 2208–2214.Google Scholar
Clark, A., Deans, B., Stevens, M., et al. (1995). Anti-tumor imidazotetrazines: synthesis of novel imidazotetrazines and related bicyclic heterocycles to probe the mode of action of the antitumor drug temozolomide. Journal of Medicinal Chemistry, 38, 1493–1504.Google Scholar
DeAngelis, L.M. (2001). Brain tumors. New England Journal of Medicine, 344, 114–123.Google Scholar
DeAngelis, L.M. (2005). Chemotherapy for brain tumors – a new beginning. New England Journal of Medicine, 352, 1036–1038.Google Scholar
DeAngelis, L.M., Burger, P., Green, S., et al. (1996). Adjuvant chemotherapy for malignant glioma: Who benefits? Annals of Neurology, 40, 491–492.Google Scholar
Denny, B., Wheelhouse, R., Stevens, M., et al. (1994). NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA. Biochemistry, 33, 9045–9051.Google Scholar
Esteller, M., Hamilton, S., Burger, P., Baylin, S., & Herman, J. (1999). Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promotor hypermethylation is a common event in primary human neoplasia. Cancer Research, 59, 793–797.Google Scholar
Esteller, M., Garcia-Foncillas, J., Andion, E., et al. (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine, 343, 1350–1354.Google Scholar
Figueroa, J., Tolcher, A., Denis, L., et al. (2000). Protracted cyclic administration of temozolomide is feasible: a phase I and pharmacokinetic-pharmacodynamic study. Proceedings of American Society Clinical Oncology, 19, 22a [Abstract 868].Google Scholar
Fine, H.A., Dear, K.B.J., Loeffler, J.S., et al. (1993). Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer, 71, 2585–2597.Google Scholar
Friedman, H., McLendon, R., Kerby, T., et al. (1998). DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. Journal of Clinical Oncology, 16, 3851–3857.Google Scholar
Gilbert, M., Olson, J., Yung, W.K.A., et al. (2000). Preirradiation treatment of newlydiagnosed anaplastic astrocytomas and glioblastoma multiforme using temozolomide. Neuro-Oncology, 2, 264 [Abstract 77].Google Scholar
Lesser, G.J., & Grossman, S. (1994). The chemotherapy of high-grade astrocytomas. Seminars in Oncology, 21, 220–235.Google Scholar
Hegi, M.E., Diserens, A.-C., Godard, S., et al. (2004). Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promotor methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research, 10, 1871–1874.Google Scholar
Hegi, M.E., Diserens, A.-C., Gorlia, T., et al. (2005). MGMT gene silencing and benefit from temozolomide in glioblastoma. New England Journal of Medicine, 352, 997–1003.Google Scholar
Ino, Y., Betensky, R., Zlatescu, M., et al. (2001). Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clinical Cancer Research, 7, 839–845.Google Scholar
Jaeckle, K., Eyre, H., Townsend, J., et al. (1998). Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. Journal of Clinical Oncology, 16, 3310–3315.Google Scholar
Medical Research Council Brain Tumor Working Party. (2001). Randomized Trial of Procarbazine, Lomustine, and Vincristine in the Adjuvant Treatment of High-Grade Astrocytoma: A Medical research Council Trial. Journal of Clinical Oncology, 19, 509–518.Google Scholar
Newlands, E., Blackledge, G., Slack, J., et al. (1992). Phase I trial of temozolomide (CCRG 81045: M and B 39831: NSC 362856). British Journal of Cancer, 65, 287–291.Google Scholar
Newlands, E.S., Blackledge, G.R.P., Slack, J.A., et al. (1996). The Charing Cross Hospital experience with temozolomide in patients with gliomas. European Journal of Cancer, 32A, 2236–2241.Google Scholar
Newlands, E., Stevens, M., Wedge, S., Wheelhouse, R., & Brock, C. (1997). Temozolomide:a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treatment Reviews, 23, 35–61.Google Scholar
Ostermann, S., Csajka, C., Buclin, T., et al. (2004). Plasma and cerebrospinal fluid population pharmacokinetics of temozolomide in malignant glioma patients. Clinical Cancer Research, 10, 3728–3736.Google Scholar
Rosenblum, M.L., Reynolds, J.A.F., Smith, K.A., et al. (1973). Chloroethyl-cyclohexyl-nitrosourea (CCNU) in the treatment of malignant brain tumors. Journal of Neurosurgery, 39, 306–314.Google Scholar
Shapiro, W., Green, S., Burger, P., et al. (1989). Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. Journal of Neurosurgery, 71, 1–9.Google Scholar
Stewart, L. (2002). Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomized trials. Lancet, 359, 1011–1018.Google Scholar
Stupp, R., Gander, M., Leyvraz, S., & Newlands, E. (2001). Current and future developments in the use of temozolomide for the treatment of brain tumors. Lancet Oncology, 2, 552–560.Google Scholar
Stupp, R., Dietrich, P.-Y., Kralijevic, S.O., et al. (2002). Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. Journal of Clinical Oncology, 20, 1375–1382.Google Scholar
Stupp, R., Mason, W.P., van den Bent, M.J., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma. New England Journal of Medicine, 352, 987–996.Google Scholar
Tolcher, A., Gerson, S., Denis, L., et al. (2003). Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. British Journal of Cancer, 88, 1004–1011.Google Scholar
van den Bent, M.J., Chinot, O.-L. , & Cairncross, J.G. (2003). Recent developments in the molecular characterization and treatment of oligodendroglial tumors. Neuro-Oncology, 5, 128–138.Google Scholar
van den Bent, M.J., Delattre, J.-Y., Brandes, A., et al. (2005). First analysis of EORTC trial 26951, a randomized phase III study of adjuvant PCV chemotherapy in patients with highly anaplastic oligodendroglioma. Proceedings of American Society Clinical Oncology, 23, 115s [Abstract 1503].Google Scholar
von Rijn, J., Heimans, J., van den Berg, J., van den Valk, P., & Slotman, B. (2000). Survival of human glioma cells treated with various combinations of temozolomide and X-rays. International Journal of Radiation Oncology Biology Physics, 47, 779–784.Google Scholar
Walker, M., Alexander, E., Hunt, W., et al. (1978). Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. Jounal of Neurosurgery, 49, 333–343.Google Scholar
Walker, M., Green, S., Byar, D., et al. (1980). Randomized comparison of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. New England Journal of Medicine, 303, 1323–1329.Google Scholar
Wedge, S., Porteous, J., Glaser, M., Marcus, K., & Newlands, E. (1997). In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs, 8, 92–97.Google Scholar
Wick, W., Wick, A., Schulz, J.B., et al. (2002). Prevention of irradiation-induced glioma cell invasion by temozolomide involves caspase 3 activity and cleavage of focal adhesion kinase. Cancer Research, 62, 1915–1919.Google Scholar
Yung, W.K.A. (2000). Temozolomide in malignant glioma. Seminars in Oncology, 27, 27–34.Google Scholar
Yung, W.K.A., Prados, M.D., Yaya-Tur, P., et al. (1999). Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Journal of Clinical Oncology, 17, 2762–2771.Google Scholar
Yung, W.K.A., Albright, R.E., Olson, J., et al. (2000). A phase II study of temozolomide versus procarbazine in patients with glioblastoma multiforme at first relapse. British Journal of Cancer, 85, 588–593.Google Scholar